Deals channel feed – Endpoints News

Deals channel feed

One of the top late-stage drugs Bristol-Myers wants in its $74B Celgene deal faces a ‘roadblock’ — analyst

7 years ago

Bristol-Myers CEO Caforio wants M&A dissidents to know there's been no 'high level' overtures about buying the company since '17

7 years ago

It’s what Bristol-Myers execs aren’t saying that makes one key analyst wonder about a potential buyout offer, looming Opdivo data and 'Plan B'

7 years ago

Jeff Marrazzo sparked a bidding war for Spark that spurred a thrifty Roche CEO to seal the winning deal with a blockbuster premium

7 years ago

Another influential voice takes Bristol-Myers’ top execs to task as they scramble to shore up the big Celgene buyout

7 years ago

From dinner in Munich to $5.85 a share, Immune Design execs pushed for every penny they could get from the Merck bargain buyout

7 years ago

As opposition mounts against Celgene deal, Bristol-Myers tells shareholders the planned buyout is the best bet in a scarce market

7 years ago

With eye on Heron's rival product, Pacira to buy MyoScience to fortify its Exparel franchise

7 years ago

Appetite for gene therapies gains momentum, as Biogen plans $800M buyout of Nightstar Therapeutics

7 years ago

Investor opposition to Bristol-Myers' $74B Celgene buyout grows as activist Starboard joins the rebellion

7 years ago

Sarepta posts early, rosy gene therapy data for limb girdle muscular dystrophy — fueling $165M buyout of partner

7 years ago

Is the $74B Celgene buyout already forcing a reckoning among Bristol-Myers Squibb’s R&D partners?

7 years ago

The Roche way: Spark found a new owner who wants to buy and build a gene therapy leader

7 years ago

Biotech M&A is back. Ipsen set to fork out up to $1.3B for rare disease specialist Clementia

7 years ago

Roche joins the M&A game, buying gene therapy pioneer Spark for $4.3B

7 years ago

Who’s in line for the next big mega-merger? Morningstar handicaps the odds among the top players

7 years ago

Starboard plots board coup after buying into Bristol-Myers in lead-up to Celgene buyout vote

7 years ago

Merck's Roger Perlmutter pays $300M to scoop up a battered Immune Design for its I/O work

7 years ago

Stock activists fire back at Allergan’s defensive moves, push for a company sale

7 years ago

J&J to augment surgical offerings with $3.4B acquisition of robotics firm Auris Health

7 years ago

'Most feared' activist investor in America has zeroed in on Bristol-Myers Squibb. Is he planning to derail the $74B Celgene buyout?

7 years ago

Playing hardball, Bristol-Myers bought out a battered Celgene with last-minute terms sweetened in its own favor

7 years ago

‘Can we stop that work, can we delay that work?’ Bristol-Myers’ top execs outline their game plan for absorbing Celgene

7 years ago

BioNTech doubles down on an antibody discovery group, scooping up a new team to play for the mRNA specialist

7 years ago

First page Previous page 104 105 106107108 109 110 Next page Last page